Jingjing Li

Jingjing Li


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2021 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
JLJingjing Li
Jingjing Li
JWJiuhong Wang
Jiuhong Wang
DLDandan Li
Dandan Li
XWXizhi Wen
Xizhi Wen
YDYa Ding
Ya Ding
XZXiaoshi Zhang
Xiaoshi Zhang
The clinical efficacy of PD-1 inhibitors as an adjuvant treatment for Asian melanoma patients has not yet been determined. This retrospective study analysed the clinical data of 90 Chinese patients with completely resected, stage III cutaneous or acral melanoma who received either adjuvant PD-1 inhibitor or high-dose interferon α-2b (HDI). Anti-PD-1 treatment resulted in significantly longer RFS and DMFS than HDI in cutaneous melanoma patients, with hazard ratios (HRs) (anti-PD-1 versus HDI) of 0.402 (95% CI, 0.183-0.886) and 0.324 (95%CI, 0.122 to 0.861) for RFS and DMFS, respectively. However, adjuvant anti-PD-1 treatment had no advantage over HDI in acral melanoma patients with HRs (anti-PD-1 versus HDI) of 1.204 (95% CI, 0.521 to 2.781) and 1.968(95% CI, 0.744-5.209) for RFS and DMFS, respectively. Adjuvant anti-PD-1 treatment yielded a significantly better prognosis than HDI in Chinese patients with stage IIIB/C cutaneous melanoma, but a significant difference was not observed in those with acral melanoma.

30 April 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LCLinbin Chen
Linbin Chen
WLWanqian Liao
Wanqian Liao
JHJing Huang
Jing Huang
QDQiuyue Ding
Qiuyue Ding
JWJunwan Wu
Junwan Wu
XZXiaoshi Zhang
Xiaoshi Zhang
Background/Objectives: Natural killer (NK) cells play a crucial role in immune surveillance against melanoma, yet they frequently exhibit dysfunction in the tumor microenvironment. This study aims to establish an NK cell activation-related prognostic signature and identify potential druggable targets to overcome NK cell dysfunction. Methods: A prognostic signature was developed using the TCGA-SKCM cohort and validated across independent datasets. NK cell activation and cytotoxicity were evaluated in melanoma-NK-92MI co-culture systems via flow cytometry. Mechanistic studies employed Western blotting, co-immunoprecipitation, ELISA, and qRT-PCR. Single-cell RNA-seq data were used to analyze cell–cell communication. Results: A four-gene NK cell activation signature was identified and validated for prognostic significance across five independent melanoma datasets. Among the identified genes, cyclin B1 (CCNB1) emerged as a novel therapeutic target for overcoming NK cell resistance. In vivo, pharmacological inhibition of the CCNB1/Cyclin-dependent kinase 1 (CDK1) complex with RO-3306 significantly suppressed melanoma growth by enhancing NK cell infiltration and IFN-γ production. In vitro, CCNB1 knockdown in melanoma cells augmented NK-92MI activation, as evidenced by increased expression of CD69, CD107a, IFN-γ, and NKG2D, thereby improving NK cell-mediated cytotoxicity. Mechanistically, in melanoma cells, the CCNB1/CDK1 complex phosphorylates STAT3, activating the IL-6/STAT3 positive feedback loop, which upregulates PD-L1 and enables resistance to NK cell-mediated cytotoxicity. Beyond its role in immune evasion, CCNB1 also promoted melanoma invasiveness by inducing epithelial–mesenchymal transition (EMT) through the TGF-β-SMAD2/3 signaling. Conclusions: This study establishes CCNB1/CDK1 as a novel immunotherapeutic target and uncovers a new role for CDK1 inhibitors in enhancing NK cell function and suppressing melanoma progression.

1 December 2022 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
JWJiuhong Wang
Jiuhong Wang
HJHang Jiang
Hang Jiang
FHFuxue Huang
Fuxue Huang
DLDandan Li
Dandan Li
XWXizhi Wen
Xizhi Wen
JLJingjing Li
Jingjing Li

1 July 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GOGuoping Ou
Guoping Ou
JGJuhua Gou
Juhua Gou
HOHongmu Ou
Hongmu Ou
HZHailin Zheng
Hailin Zheng
YZYuanying Zhu
Yuanying Zhu
XLXiaohua Liu
Xiaohua Liu
This project aimed to discover independent gut markers of immunotherapy based on qPCR method. 80 metastatic melanoma patients receiving immunotherapy were enrolled in this study, and the relative abundance of 41 gut markers was worked out by a newly established qPCR method. The HR of these gut markers was calculated using Rstudio-coxph. The associations between these 41 gut markers and age as well as treatment-course were analyzed by heatmap, linear-regression or VIF. Markers for Cox prediction model were selected according to the results of HR, VIF and LASSO regression. Nomogram, calibration curves for nomogram and stratified survival analysis were used to observe the predictive performance of the prediction model and related gut markers. BloUP may be associated with pseudoresponse of immunotherapy, especially in elderly patients. Age (risk**), treatment-type*, treatment-course (protective), clinical-response**, LDH (risk), Amc (risk**), Bvu (protective), Cpe (protective) and Rgn (risk) were recommended as predictors of immunotherapy. For patients with Age> 55 or LDH> 196, the detection of Amc could further predict the prognosis (p = 0.065, p = 0.013). For patients with Age< 55 or LDH< 196, the detection of Bvu could further predict the prognosis (p = 0.007, p = 0.011). For patients with Amc< 0.76 or Bvu > 0.84, longer treatment duration (treatment-course> 10) will significantly improve prognosis (p < 0.001, p = 0.007). AmcLOW and BvuUP marked good immunotherapy responsiveness in melanoma patients, the detection of Amc and Bvu may had potential impacts on immunotherapy strategies. Further detection of gut markers (Amc and Bvu) could better predict patients’ responsiveness to immunotherapy. Revealed the predictive power of 41 gut markers in immunotherapy. Proposed that BloUP may be associated with pseudoresponse in elderly patients. Recommended Amc and Bvu as independent predictive markers of immunotherapy. Proposed that AmcLOW and BvuUP marked good immunotherapy responsiveness in melanoma patients, and the detection of Amc and Bvu may had potential impacts on immunotherapy strategies.

31 March 2026 in Journal of Otolaryngology - Head & Neck Surgery
Verified
Journal Article
Open access
QDQiuyue Ding
Qiuyue Ding
JWJunwan Wu
Junwan Wu
YDYa Ding
Ya Ding
DLDandan Li
Dandan Li
XWXizhi Wen
Xizhi Wen
JLJingjing Li
Jingjing Li
Importance: The currently recommended postoperative adjuvant treatment for sinonasal mucosal melanoma (SNMM) (chemotherapy, optionally accompanied by local radiotherapy) has limited efficacy. Objective: We aimed to provide a potentially optimal adjuvant therapeutic strategy for patients with SNMM. Design: Retrospective cohort study. Setting: Our hospital’s cancer center. Participants: Seventy-nine patients with stage III/IV SNMM who underwent complete resection and received adjuvant radiotherapy between April 2012 and October 2022 were included in the study. Interventions: Patients were categorized into 2 groups based on different adjuvant medical regimens: a temozolomide/dacarbazine-based chemotherapy group (n = 44) and a temozolomide/dacarbazine chemotherapy plus PD-1 inhibitor group (n = 35). Main outcome measures: These included recurrence-free survival (RFS), distant metastasis-free survival (DMFS), failure patterns, and overall survival (OS). Results: The median follow-up duration was 56.8 (8.85-104.75) months in the chemotherapy group and 27.7 (14.53-40.87) months in the chemotherapy plus PD-1 inhibitor group, respectively. Relative to adjuvant chemoradiotherapy, the combination of additional PD-1 inhibitor significantly prolonged RFS (mRFS: 10.0 months vs 18.9 months; HR, 0.43; 95% CI, 0.25-0.75; P = .002), DMFS (mDMFS: 11.2 months vs 18.9 months; HR, 0.48; 95% CI, 0.27-0.84; P = .009), and OS (29.1 months vs NA; HR, 0.36; 95% CI, 0.17-0.77; P = .006) in patients with SNMM. Within a 2-year timeframe, patients in the chemotherapy plus PD-1 inhibitor group exhibited a lower regional recurrence rate than those in the chemotherapy group (0.0% vs 18.8%, P < .001). The 2-year OS rates in the adjuvant chemotherapy group and the chemotherapy combined with PD-1 inhibitor group were 54.5% versus 75.7%, respectively, while the corresponding 4-year OS rates were 20.9% and 62.4%. Conclusions and relevance: Surgery followed by adjuvant chemoradiotherapy and prompt initiation of PD-1 inhibitor therapy may improve local disease control in patients with SNMM.

27 July 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JZJunjie Zhen
Junjie Zhen
RZRongcheng Zhang
Rongcheng Zhang
DLDandan Li
Dandan Li
YDYa Ding
Ya Ding
XWXizhi Wen
Xizhi Wen
JLJingjing Li
Jingjing Li
Background: Leptomeningeal metastases (LM) from melanoma are rare and associated with dismal outcomes. Intrathecal PD-1 antibody therapy has shown encouraging activity in LM. Radiotherapy may enhance tumor immunogenicity and potentially augment immune checkpoint blockade within the central nervous system. The efficacy and safety of combining intrathecal PD-1 antibodies with whole-brain radiotherapy (WBRT) in melanoma LM remain unclear. Methods: We retrospectively reviewed melanoma patients with LM who received intrathecal PD-1 antibody therapy between June 2022 and December 2024. Patients were categorized according to whether WBRT was administered within 30 days of intrathecal PD-1 antibody therapy: intrathecal monotherapy and combination therapy. Overall survival (OS) and intracranial progression-free survival (iPFS) were descriptively evaluated by treatment exposure, with between-group analyses considered exploratory and hypothesis-generating. Adverse events were graded using CTCAE v5.0. Results: 20 patients were included, of whom 7 received intrathecal PD-1 antibody monotherapy and 13 received intrathecal PD-1 antibody therapy combined with WBRT. The observed median OS was 20.1 weeks (95% CI, 13.3-not reached) in the intrathecal monotherapy group and 45.3 weeks (95% CI, 28.7-not reached) in the combination group. The observed median iPFS was 10.0 weeks (95% CI, 6.1-not reached) and 23.0 weeks (95% CI, 18.4-not reached), respectively. Treatment-related adverse events were manageable, and no new safety signals were identified. Conclusion: Intrathecal PD-1 antibody therapy combined with WBRT showed numerically longer OS and iPFS than intrathecal therapy alone in this small retrospective descriptive series of melanoma leptomeningeal metastasis. These hypothesis-generating findings warrant prospective investigation but do not establish comparative efficacy.